Carlos Ramos, MD
Obstetrics & Gynecology · Houston, TXNPI 1841292117
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,335 of the $9,597 with a category attached, or 86.8%. Novartis accounts for 87.8% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $6,653 and has fallen 99.0% since, to $67 in 2025. Among obstetrics & gynecology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 63 payments — averaging $152.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$8K
- AbbVie$220
- Myovant Sciences Inc.$149
- Astellas Pharma US Inc$137
- Bayer$123
- Coopersurgical, Inc.$75
- plus $465 from 18 others
What the payments were for
- Consulting fees$8,33587%
- Food & beverage$1,24513%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 4 | $8,429 |
| AbbVie | 12 | $220 |
| Myovant Sciences Inc. | 6 | $149 |
| Astellas Pharma US Inc | 7 | $137 |
| Bayer | 6 | $123 |
| Coopersurgical, Inc. | 4 | $75 |
| Hologic Sales And Service, LLC | 3 | $57 |
| Aspira Women's Health Inc | 2 | $48 |
| Pfizer | 3 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $47 |
| Smith+Nephew | 1 | $29 |
| Evofem Biosciences, Inc. | 1 | $23 |
| Medtronic | 1 | $22 |
| Spectrum Pharmaceuticals Inc. | 1 | $22 |
| Mylan Pharmaceuticals Inc. | 1 | $20 |
| Renovia Inc | 1 | $20 |
| Organon | 1 | $19 |
| Agile Therapeutics, Inc. | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Medicem Inc. | 1 | $17 |
| Millicent US Inc | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Merck | 1 | $13 |
| Therapeuticsmd, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KYMRIAH$8,335
How this compares
$9,597 in reported general payments places this provider in the 90th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 54 | $4,871 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Houston
- George KuhnHouston$244K
- Daisy AyimHouston$188K
- Shannon WestinHouston$176K
- Asha BhalwalHouston$151K
- Nicole TranHouston$133K
- Sandra HurtadoHouston$123K
- Alvaro MontealegreHouston$92K
- Patti RossHouston$72K
- Damla KarsanHouston$58K
- Christopher JayneHouston$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.